Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy

David B K Golden, Deborah A. Meyers, Anne Kagey-Sobotka, Martin D. Valentine, Lawrence M. Lichtenstein

Research output: Contribution to journalArticle

Abstract

Parameters associated with successful venom immunotherapy in insect allergy were sought by comparison of treatment failures with successes. Half-dose treatment was completely protective in 32 patients (successes) but was only partially effective in eight (failures). The outcome of treatment was not related to the severity of pretreatment sting reactions, to the degree of skin-test sensitivity, to an atopic personal history, or to age or gender. The mean yellow jacket venom-specific IgG antibody level (by the Staph-A solid-phase radioimmunoassay) was significantly less in the failures (3.9 ± 0.6 μg/ml) than in the successes (7.3 ± 1.1 μg/ml) (p <0.01). When the failures were successfully treated, their mean IgG level (6.1 ± 1.3 μg/ml) was significantly greater than that associated with treatment failure (p <0.025). Patients with an IgG antibody level above 5.0 μg/ml were significantly more likely to be fully protected (p <0.02). Those whose IgG levels were less than 5 μg/ml had a risk of reaction similar to that in untreated patients. We conclude that early in the maintenance phase of low-dose venom immunotherapy, the risk of a reaction to a challenge sting is significantly greater for those patients with low levels of venom-specific IgG antibodies.

Original languageEnglish (US)
Pages (from-to)489-493
Number of pages5
JournalThe Journal of Allergy and Clinical Immunology
Volume69
Issue number6
DOIs
StatePublished - 1982

Fingerprint

Venoms
Immunotherapy
Immunoglobulin G
Antibodies
Bites and Stings
Treatment Failure
Wasps
Skin Tests
Radioimmunoassay
Insects
Hypersensitivity
Maintenance

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. / Golden, David B K; Meyers, Deborah A.; Kagey-Sobotka, Anne; Valentine, Martin D.; Lichtenstein, Lawrence M.

In: The Journal of Allergy and Clinical Immunology, Vol. 69, No. 6, 1982, p. 489-493.

Research output: Contribution to journalArticle

@article{cf24f429e5c043279659b037ba1cf108,
title = "Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy",
abstract = "Parameters associated with successful venom immunotherapy in insect allergy were sought by comparison of treatment failures with successes. Half-dose treatment was completely protective in 32 patients (successes) but was only partially effective in eight (failures). The outcome of treatment was not related to the severity of pretreatment sting reactions, to the degree of skin-test sensitivity, to an atopic personal history, or to age or gender. The mean yellow jacket venom-specific IgG antibody level (by the Staph-A solid-phase radioimmunoassay) was significantly less in the failures (3.9 ± 0.6 μg/ml) than in the successes (7.3 ± 1.1 μg/ml) (p <0.01). When the failures were successfully treated, their mean IgG level (6.1 ± 1.3 μg/ml) was significantly greater than that associated with treatment failure (p <0.025). Patients with an IgG antibody level above 5.0 μg/ml were significantly more likely to be fully protected (p <0.02). Those whose IgG levels were less than 5 μg/ml had a risk of reaction similar to that in untreated patients. We conclude that early in the maintenance phase of low-dose venom immunotherapy, the risk of a reaction to a challenge sting is significantly greater for those patients with low levels of venom-specific IgG antibodies.",
author = "Golden, {David B K} and Meyers, {Deborah A.} and Anne Kagey-Sobotka and Valentine, {Martin D.} and Lichtenstein, {Lawrence M.}",
year = "1982",
doi = "10.1016/0091-6749(82)90172-5",
language = "English (US)",
volume = "69",
pages = "489--493",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy

AU - Golden, David B K

AU - Meyers, Deborah A.

AU - Kagey-Sobotka, Anne

AU - Valentine, Martin D.

AU - Lichtenstein, Lawrence M.

PY - 1982

Y1 - 1982

N2 - Parameters associated with successful venom immunotherapy in insect allergy were sought by comparison of treatment failures with successes. Half-dose treatment was completely protective in 32 patients (successes) but was only partially effective in eight (failures). The outcome of treatment was not related to the severity of pretreatment sting reactions, to the degree of skin-test sensitivity, to an atopic personal history, or to age or gender. The mean yellow jacket venom-specific IgG antibody level (by the Staph-A solid-phase radioimmunoassay) was significantly less in the failures (3.9 ± 0.6 μg/ml) than in the successes (7.3 ± 1.1 μg/ml) (p <0.01). When the failures were successfully treated, their mean IgG level (6.1 ± 1.3 μg/ml) was significantly greater than that associated with treatment failure (p <0.025). Patients with an IgG antibody level above 5.0 μg/ml were significantly more likely to be fully protected (p <0.02). Those whose IgG levels were less than 5 μg/ml had a risk of reaction similar to that in untreated patients. We conclude that early in the maintenance phase of low-dose venom immunotherapy, the risk of a reaction to a challenge sting is significantly greater for those patients with low levels of venom-specific IgG antibodies.

AB - Parameters associated with successful venom immunotherapy in insect allergy were sought by comparison of treatment failures with successes. Half-dose treatment was completely protective in 32 patients (successes) but was only partially effective in eight (failures). The outcome of treatment was not related to the severity of pretreatment sting reactions, to the degree of skin-test sensitivity, to an atopic personal history, or to age or gender. The mean yellow jacket venom-specific IgG antibody level (by the Staph-A solid-phase radioimmunoassay) was significantly less in the failures (3.9 ± 0.6 μg/ml) than in the successes (7.3 ± 1.1 μg/ml) (p <0.01). When the failures were successfully treated, their mean IgG level (6.1 ± 1.3 μg/ml) was significantly greater than that associated with treatment failure (p <0.025). Patients with an IgG antibody level above 5.0 μg/ml were significantly more likely to be fully protected (p <0.02). Those whose IgG levels were less than 5 μg/ml had a risk of reaction similar to that in untreated patients. We conclude that early in the maintenance phase of low-dose venom immunotherapy, the risk of a reaction to a challenge sting is significantly greater for those patients with low levels of venom-specific IgG antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0019976840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019976840&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(82)90172-5

DO - 10.1016/0091-6749(82)90172-5

M3 - Article

C2 - 7076990

AN - SCOPUS:0019976840

VL - 69

SP - 489

EP - 493

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6

ER -